# Munich Cancer Registry

## ICD-10 C51-C58: Fem. genitale cancer

## Survival

| Year of diagnosis | 1988-1997 | 1998-2020 |
|---|---|---|
| Patients | 5,423 | 29,325 |
| Diseases | 5,485 | 29,952 |
| Cases evaluated | 4,914 | 23,291 |
| Creation date | 04/15/2022 | |
| Database export | 12/20/2021 | |
| Population (females) | 2.48 m | |

Munich Cancer Registry
Cancer Registry Bavaria - Upper Bavaria Regional Center
at Klinikum Grosshadern/IBE
Marchioninistr. 15
Munich, 81377
Germany

https://www.tumorregister-muenchen.de/en

https://www.tumorregister-muenchen.de/en/facts/surv/sC5158E-ICD-10-C51-C58-Fem.-genitale-cancer-survival.pdf

## Index of figures and tables

ICD-10 C51-C58: Malignant neoplasms of female genital organs
Period of diagnosis
*Relative survival 1988-2020*



**Figure 1a.** Relative survival of patients with fem. genitale cancer by period of diagnosis. Included in the evaluation are 28,047 cases diagnosed between 1988 and 2020.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 2000 to 2018, and are represented by colored diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided population-based statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

| | Period of diagnosis | | | | | | | |
| | 1988-1997 n=4,910 | | 1998-2006 n=7,647 | | 2007-2015 n=10,412 | | 2016+ n=5,078 | |
| Years | obs. % | rel. % | obs. % | rel. % | obs. % | rel. % | obs. % | rel. % |
|---|---|---|---|---|---|---|---|---|
| 0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| 1 | 87.0 | 88.9 | 85.1 | 87.1 | 85.9 | 87.6 | 87.3 | 88.9 |
| 2 | 76.3 | 79.5 | 75.4 | 78.6 | 76.5 | 79.5 | 79.7 | 82.5 |
| 3 | 69.6 | 74.1 | 68.4 | 72.6 | 70.2 | 74.1 | 73.3 | 77.1 |
| 4 | 64.8 | 70.2 | 63.8 | 68.9 | 65.4 | 70.3 | 68.7 | 73.3 |
| 5 | 61.3 | 67.9 | 60.4 | 66.4 | 61.8 | 67.5 | 64.3 | 69.8 |
| 6 | 58.5 | 66.0 | 57.3 | 64.1 | 58.7 | 65.3 | | |
| 7 | 55.6 | 64.0 | 54.9 | 62.5 | 56.0 | 63.4 | | |
| 8 | 53.3 | 62.6 | 52.8 | 61.3 | 54.0 | 62.2 | | |
| 9 | 50.9 | 61.0 | 50.9 | 60.3 | 52.1 | 61.2 | | |
| 10 | 49.3 | 60.2 | 49.3 | 59.5 | 50.3 | 60.3 | | |
| 11 | 47.3 | 59.0 | 47.6 | 58.6 | 48.6 | 59.4 | | |
| 12 | 45.8 | 58.3 | 46.0 | 57.8 | 46.9 | 58.5 | | |
| 13 | 44.2 | 57.4 | 44.1 | 56.6 | 45.2 | 57.5 | | |
| 14 | 42.4 | 56.2 | 42.1 | 55.2 | 42.5 | 55.4 | | |
| 15 | 40.6 | 55.0 | 40.6 | 54.4 | | | | |
| Median | 9.5 | | 9.6 | | 10.1 | | | |

**Table 1b.** Observed (obs.) and relative (rel.) survival of patients with fem. genitale cancer by period of diagnosis for period 1988-2020 (N=28,047).

ICD-10 C51-C58: Malignant neoplasms of female genital organs
Total cohort
*Survival 1998-2020*



**Figure 2a.** Observed, expected and relative survival of the total cohort with fem. genitale cancer. Included in the evaluation are 23,137 cases diagnosed between 1998 and 2020.

| | Group | |
| | All patients | |
| | n=23,137 | |
| Years | obs. % | rel. % |
|---|---|---|
| 0 | 100.0 | 100.0 |
| 1 | 85.9 | 87.7 |
| 2 | 76.8 | 79.8 |
| 3 | 70.2 | 74.2 |
| 4 | 65.5 | 70.4 |
| 5 | 61.9 | 67.7 |
| 6 | 58.7 | 65.4 |
| 7 | 56.2 | 63.6 |
| 8 | 54.1 | 62.4 |
| 9 | 52.2 | 61.4 |
| 10 | 50.4 | 60.5 |
| 11 | 48.7 | 59.6 |
| 12 | 47.1 | 58.8 |
| 13 | 45.2 | 57.6 |
| 14 | 43.1 | 56.2 |
| 15 | 41.5 | 55.3 |
| Median | 10.3 | |

**Table 2b.** Observed (obs.) and relative (rel.) survival of the total cohort with fem. genitale cancer for period 1998-2020 (N=23,137).

**Figure 3a.** Observed survival of patients with fem. genitale cancer by age category. Included in the evaluation are 23,137 cases diagnosed between 1998 and 2020.



**Figure 3b.** Relative survival of patients with fem. genitale cancer by age category. Included in the evaluation are 23,137 cases diagnosed between 1998 and 2020.

| | Age category | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | 0-49 yrs n=4,216 | | 50-59 yrs n=4,354 | | 60-69 yrs n=5,776 | | 70-79 yrs n=5,538 | | 80+ yrs n=3,253 | |
| Years | obs. % | rel. % | obs. % | rel. % | obs. % | rel. % | obs. % | rel. % | obs. % | rel. % |
| 0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| 1 | 95.3 | 95.4 | 92.9 | 93.3 | 90.3 | 91.0 | 82.8 | 84.6 | 62.5 | 68.5 |
| 2 | 90.7 | 90.8 | 85.4 | 86.0 | 81.9 | 83.3 | 71.3 | 74.7 | 48.4 | 58.1 |
| 3 | 86.1 | 86.4 | 80.5 | 81.4 | 75.3 | 77.3 | 63.3 | 68.1 | 39.3 | 52.1 |
| 4 | 83.5 | 83.8 | 76.0 | 77.2 | 70.6 | 73.3 | 57.8 | 64.0 | 33.1 | 48.8 |
| 5 | 81.2 | 81.7 | 73.1 | 74.6 | 66.9 | 70.2 | 53.9 | 61.8 | 27.7 | 45.9 |
| 6 | 79.3 | 79.9 | 70.7 | 72.6 | 64.0 | 67.9 | 50.0 | 59.5 | 23.1 | 43.5 |
| 7 | 78.1 | 78.8 | 68.6 | 70.8 | 61.6 | 66.3 | 46.5 | 57.5 | 19.5 | 42.0 |
| 8 | 77.4 | 78.2 | 67.4 | 70.0 | 59.5 | 65.0 | 43.3 | 56.3 | 16.5 | 41.3 |
| 9 | 76.4 | 77.4 | 66.3 | 69.4 | 58.0 | 64.4 | 40.3 | 55.0 | 13.7 | 40.5 |
| 10 | 76.0 | 77.1 | 64.9 | 68.4 | 56.6 | 64.0 | 37.9 | 54.8 | 10.8 | 38.2 |
| 11 | 75.4 | 76.7 | 64.0 | 68.0 | 54.8 | 63.2 | 34.6 | 53.4 | 9.3 | 40.3 |
| 12 | 74.8 | 76.2 | 62.9 | 67.4 | 53.4 | 63.0 | 31.6 | 52.6 | 7.7 | 41.3 |
| 13 | 74.0 | 75.7 | 61.6 | 66.7 | 51.7 | 62.6 | 27.9 | 50.4 | 5.9 | 40.3 |
| 14 | 73.1 | 75.0 | 60.1 | 65.7 | 48.9 | 60.9 | 24.6 | 49.0 | 4.9 | 43.8 |
| 15 | 72.5 | 74.6 | 58.7 | 64.9 | 47.4 | 60.8 | 21.8 | 48.1 | 3.7 | 44.5 |
| Median | | | 22.2 | | 13.7 | | 6.0 | | 1.9 | |

**Table 3c.** Observed (obs.) and relative (rel.) survival of patients with fem. genitale cancer by age category for period 1998-2020 (N=23,137).

ICD-10 C51-C58: Malignant neoplasms of female genital organs
ICD-10 classification
*Relative survival 1998-2020*



**Figure 4a.** Relative survival of patients with fem. genitale cancer by ICD-10 classification. Included in the evaluation are 23,137 cases diagnosed between 1998 and 2020.

| | ICD-10 classification | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | C51 Vulva n=1,649 | | C52 Vagina n=273 | | C53 Cervix uteri n=4,453 | | C54 Corpus uteri n=9,842 | | C55 Uterus unspec. n=101 | | C56 Ovary n=6,192 | | C57 Female genitals unspec. n=601 | |
| Years | obs. % | rel. % | obs. % | rel. % | obs. % | rel. % | obs. % | rel. % | obs. % | rel. % | obs. % | rel. % | obs. % | rel. % |
| 0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| 1 | 85.1 | 88.3 | 71.4 | 74.2 | 88.4 | 89.3 | 91.6 | 93.6 | 68.2 | 69.8 | 76.8 | 78.5 | 81.0 | 82.8 |
| 2 | 73.7 | 79.2 | 55.8 | 59.8 | 80.2 | 81.5 | 85.2 | 88.9 | 61.4 | 63.9 | 63.8 | 66.1 | 69.1 | 71.9 |
| 3 | 68.0 | 75.4 | 48.4 | 53.2 | 74.8 | 76.5 | 80.4 | 85.7 | 60.2 | 63.6 | 53.3 | 56.1 | 59.3 | 62.7 |
| 4 | 62.4 | 71.2 | 45.4 | 51.2 | 71.6 | 73.7 | 76.7 | 83.4 | 56.6 | 61.1 | 46.3 | 49.4 | 53.9 | 58.2 |
| 5 | 59.0 | 69.2 | 41.8 | 48.3 | 68.7 | 71.1 | 73.7 | 81.8 | 49.4 | 54.5 | 41.4 | 44.8 | 50.6 | 55.7 |
| 6 | 56.0 | 67.6 | 39.9 | 47.8 | 66.8 | 69.6 | 70.4 | 80.0 | 44.3 | 49.9 | 37.5 | 41.2 | 46.9 | 52.7 |
| 7 | 52.9 | 65.7 | 35.8 | 44.0 | 65.3 | 68.4 | 67.8 | 78.8 | 40.5 | 46.3 | 34.5 | 38.5 | 42.7 | 49.0 |
| 8 | 48.7 | 62.4 | 34.7 | 43.3 | 63.9 | 67.4 | 65.6 | 78.0 | 40.5 | 46.3 | 32.6 | 37.0 | 40.8 | 47.7 |
| 9 | 45.5 | 60.0 | 30.7 | 40.0 | 63.0 | 66.8 | 63.4 | 77.3 | 40.5 | 46.4 | 30.9 | 35.6 | 39.0 | 46.8 |
| 10 | 43.9 | 59.3 | 28.2 | 37.5 | 62.1 | 66.3 | 61.2 | 76.5 | 40.5 | 46.4 | 29.4 | 34.4 | 37.7 | 46.1 |
| Median | 7.5 | | 2.7 | | | | 14.6 | | 4.9 | | 3.4 | | 5.3 | |

| | ICD-10 classification | |
|---|---|---|
| *cont'd* | C58 Placenta n=26 | |
| Years | obs. % | rel. % |
| 0 | 100.0 | 100.0 |
| Median | | |

**Table 4b.** Observed (obs.) and relative (rel.) survival of patients with fem. genitale cancer by ICD-10 classification for period 1998-2020 (N=23,137).

ICD-10 C51-C58: Malignant neoplasms of female genital organs
Extent of disease
*Relative survival 1998-2020*



**Figure 4e.** Relative survival of patients with fem. genitale cancer by extent of disease. For 21,782 of 23,137 cases diagnosed between 1998 and 2020 valid data could be obtained for this item. For a total of 21,649 cases an evaluable classification was established. The grey line represents the subgroup of 1,488 patients with missing values regarding extent of disease (6.4 % of 23,137 patients, the percent values of all other categories are related to n=21,649).

| | **Extent of disease** | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | Local n=15,935 | | Regional n=3,100 | | Distant n=2,614 | | NA/NOS n=1,488 | |
| Years | obs. % | rel. % | obs. % | rel. % | obs. % | rel. % | obs. % | rel. % |
| 0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| 1 | 92.8 | 94.6 | 85.2 | 86.5 | 56.1 | 57.4 | 66.8 | 69.4 |
| 2 | 86.4 | 89.7 | 70.1 | 72.1 | 37.7 | 39.1 | 56.7 | 60.6 |
| 3 | 81.3 | 85.9 | 59.5 | 62.0 | 26.9 | 28.3 | 50.1 | 54.6 |
| 4 | 77.3 | 83.1 | 51.8 | 54.6 | 21.0 | 22.4 | 46.4 | 51.4 |
| 5 | 73.8 | 80.9 | 46.8 | 50.1 | 17.2 | 18.7 | 44.1 | 49.7 |
| 6 | 70.8 | 78.9 | 42.7 | 46.1 | 14.3 | 15.8 | 41.6 | 47.7 |
| 7 | 67.9 | 77.2 | 39.8 | 43.5 | 12.6 | 14.2 | 40.3 | 46.7 |
| 8 | 65.7 | 76.1 | 37.1 | 41.2 | 11.6 | 13.2 | 39.0 | 46.0 |
| 9 | 63.5 | 75.0 | 35.5 | 39.9 | 10.9 | 12.8 | 37.5 | 44.9 |
| 10 | 61.5 | 74.2 | 34.2 | 39.0 | 9.9 | 11.7 | 36.4 | 44.1 |
| Median | 15.3 | | 4.3 | | 1.3 | | 3.0 | |

**Table 4f.** Observed (obs.) and relative (rel.) survival of patients with fem. genitale cancer by extent of disease for period 1998-2020 (N=21,649).

ICD-10 C51-C58: Malignant neoplasms of female genital organs
Extent of disease
*Conditional relative 5 year survival 1998-2020*          N=21,649



**Figure 4i.** Conditional relative 5-year survival of patients with fem. genitale cancer by extent of disease. For 21,782 of 23,137 cases diagnosed between 1998 and 2020 valid data could be obtained for this item. For a total of 21,649 cases an evaluable classification was established. The grey line represents the subgroup of 1,488 patients with missing values regarding extent of disease (6.4 % of 23,137 patients, the percent values of all other categories are related to n=21,649).

| | **Extent of disease** | | | | | | | |
| | Local | | Regional | | Distant | | NA/NOS | |
| | | Cond. surv. % | | Cond. surv. % | | Cond. surv. % | | Cond. surv. % |
| Years | n | 5 yrs | n | 5 yrs | n | 5 yrs | n | 5 yrs |
| 0 | 15,935 | 80.9 | 3,100 | 50.1 | 2,614 | 18.7 | 1,488 | 49.7 |
| 1 | 14,173 | 83.7 | 2,549 | 53.4 | 1,421 | 27.6 | 945 | 69.0 |
| 2 | 12,604 | 86.6 | 2,004 | 60.5 | 900 | 36.5 | 766 | 77.9 |
| 3 | 11,192 | 89.4 | 1,615 | 66.6 | 598 | 46.9 | 646 | 85.4 |
| 4 | 9,958 | 91.4 | 1,312 | 73.4 | 426 | 57.4 | 561 | 88.8 |
| 5 | 8,886 | 93.1 | 1,095 | 78.3 | 321 | 63.6 | 511 | 90.5 |
| 6 | 7,998 | 94.3 | 930 | 83.5 | 245 | 73.8 | 458 | 92.7 |
| 7 | 7,132 | 95.5 | 785 | 86.3 | 191 | 80.3 | 428 | 93.0 |
| 8 | 6,358 | 95.5 | 670 | 89.2 | 159 | 81.7 | 394 | 91.1 |
| 9 | 5,616 | 95.0 | 570 | 88.5 | 132 | 77.8 | 353 | 90.0 |
| 10 | 4,944 | 95.1 | 495 | 87.9 | 102 | 79.4 | 318 | 90.7 |

**Table 4j.** Conditional relative 5-year survival of patients with fem. genitale cancer by extent of disease for period 1998-2020 (N=21,649).

Conditional relative survival rates refer to the relative survival probability, in this case for 5 years after cancer diagnosis, compared to the age- and sex-matched population (=100 %) under the condition of being alive for a certain time period (x-axis in Figure 4g). The results illustrate to what extent the cancer induced mortality of particular subgroups declines in the subsequent years after detection of the malignancy. For instance, according to the presented survival statistics, patients in the subgroup extent of disease="Local", who are alive at least 3 years after cancer diagnosis, the conditional relative 5-year survival rate is 89.4% (n=11,192).

ICD-10 C51-C58: Malignant neoplasms of female genital organs
Progressionsform
*Time to first progression (TTP) 1998-2020*  N=23,059



**Figure 5a.** Time to first progression of 23,059 patients with fem. genitale cancer diagnosed between 1998 and 2020 (in solid cancers M0 only) estimated by cumulative incidence function (CI, solid line) accounting for death as competing risk and by inverse Kaplan-Meier estimate (1-KM, dashed line). The frequency of events may be underestimated due to underreporting.

| | Type of progression | | | | | | |
|---|---|---|---|---|---|---|---|
| | Any type (CI) | Any type (1-KM) | Local relapse (CI) | Local relapse (1-KM) | Lymph node (CI) | Lymph node (1-KM) | Distant metastasis (CI) |
| N | 20,551 | 20,551 | 23,059 | 23,059 | 23,059 | 23,059 | 20,551 |
| Events | 7,154 | 7,154 | 3,515 | 3,515 | 1,008 | 1,008 | 4,347 |
| compet. | 2,610 | | 7,826 | | 9,817 | | 4,661 |
| Years | % | % | % | % | % | % | % |
| 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| 1 | 15.7 | 15.8 | 4.6 | 5.1 | 1.2 | 1.3 | 6.9 |
| 2 | 24.9 | 25.3 | 9.6 | 11.0 | 2.4 | 2.9 | 13.0 |
| 3 | 29.7 | 30.4 | 12.4 | 14.5 | 3.3 | 4.0 | 16.7 |
| 4 | 32.3 | 33.2 | 13.9 | 16.6 | 3.8 | 4.7 | 18.9 |
| 5 | 34.0 | 35.0 | 14.9 | 18.0 | 4.2 | 5.3 | 20.3 |
| 6 | 35.2 | 36.3 | 15.5 | 18.8 | 4.4 | 5.6 | 21.4 |
| 7 | 36.0 | 37.2 | 16.0 | 19.6 | 4.5 | 5.9 | 22.0 |
| 8 | 36.6 | 37.9 | 16.3 | 20.0 | 4.6 | 6.1 | 22.5 |
| 9 | 37.1 | 38.5 | 16.5 | 20.4 | 4.8 | 6.3 | 22.9 |
| 10 | 37.5 | 39.0 | 16.7 | 20.8 | 4.9 | 6.5 | 23.2 |
| 11 | 37.8 | 39.4 | 16.9 | 21.0 | 4.9 | 6.6 | 23.5 |
| 12 | 38.1 | 39.7 | 17.0 | 21.2 | 5.0 | 6.8 | 23.7 |
| 13 | 38.3 | 40.1 | 17.1 | 21.4 | 5.0 | 6.8 | 24.0 |
| 14 | 38.6 | 40.4 | 17.2 | 21.6 | 5.1 | 6.9 | 24.2 |
| 15 | 38.9 | 40.8 | 17.4 | 21.9 | 5.1 | 6.9 | 24.3 |

| | Type of progression | | |
| --- | --- | --- | --- |
| *cont'd* | Distant metast. (1-KM) | NOS (CI) | NOS (1-KM) |
| N | 20,551 | 23,059 | 23,059 |
| Events | 4,347 | 2,124 | 2,124 |
| compet. | | 8,729 | |
| Years | % | % | % |
| 0 | 0.0 | 0.0 | 0.0 |
| 1 | 7.2 | 5.9 | 6.2 |
| 2 | 13.8 | 7.7 | 8.3 |
| 3 | 18.0 | 8.4 | 9.3 |
| 4 | 20.6 | 8.9 | 9.8 |
| 5 | 22.3 | 9.1 | 10.2 |
| 6 | 23.5 | 9.3 | 10.5 |
| 7 | 24.4 | 9.4 | 10.7 |
| 8 | 25.1 | 9.5 | 10.8 |
| 9 | 25.6 | 9.6 | 11.0 |
| 10 | 25.9 | 9.6 | 11.1 |
| 11 | 26.4 | 9.7 | 11.2 |
| 12 | 26.7 | 9.8 | 11.3 |
| 13 | 27.1 | 9.8 | 11.4 |
| 14 | 27.4 | 9.9 | 11.6 |
| 15 | 27.6 | 10.0 | 11.8 |

**Table 5b.** Time to first progression of patients with fem. genitale cancer for period 1998-2020 (N=23,059), also showing the total of progression events (Events) and of deaths as competing risk (compet.).

ICD-10 C51-C58: Malignant neoplasms of female genital organs
Progression type
*Observed post-progression survival 1998-2020*



**Figure 5c.** Observed post-progression survival of 7,604 patients with fem. genitale cancer diagnosed between 1998 and 2020. These 7,604 patients with documented progression events during their course of disease represent 33.0 % of the totally 23,059 evaluated cases (incl. M1, n=2,508, 10.9 %). Patients with cancer relapse documented via death certificates only were excluded (n=2,085, 9.0 %). Multiple progression types on different sites are included in the evaluation even when not occuring synchronously. The NOS (not otherwise specified) class is included under the condition, that it is the one and only progression type during the course of disease.

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement "not specified" is the only information in registries regarding relapse of the disease. The category "Any type" denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100 % value because patients are potientially considered in more than one subgroup.

| | Type of progression | | | | |
|---|---|---|---|---|---|
| | Any type | Local relapse | Lymph node | Distant metastasis | NOS |
| | n=7,604 | n=3,105 | n=1,009 | n=5,399 | n=1,130 |
| Years | % | % | % | % | % |
| 0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| 1 | 60.0 | 62.3 | 63.3 | 54.0 | 61.2 |
| 2 | 41.6 | 43.9 | 43.1 | 35.0 | 42.0 |
| 3 | 31.8 | 34.2 | 33.9 | 24.6 | 33.5 |
| 4 | 25.3 | 27.3 | 25.3 | 19.0 | 26.5 |
| 5 | 21.3 | 23.0 | 21.2 | 15.6 | 22.3 |
| 6 | 18.6 | 20.2 | 18.9 | 13.1 | 20.4 |
| 7 | 16.7 | 18.4 | 16.7 | 11.7 | 18.1 |
| 8 | 15.3 | 16.7 | 14.9 | 10.5 | 16.6 |
| 9 | 14.4 | 15.1 | 14.4 | 10.1 | 15.7 |
| 10 | 13.1 | 13.8 | 13.3 | 9.2 | 14.0 |

**Table 5d.** Observed post-progression survival of patients with fem. genitale cancer for period 1998-2020 (N=7,604).

ICD-10 C51-C58: Malignant neoplasms of female genital organs
Type of Progression: Distant metastasis
*Observed post-progression survival by period of progression date 1988-2020*          N=6,224



**Figure 5e.** Observed post-progression (distant metastasis) survival of 6,224 patients with fem. genitale cancer diagnosed between 1988 and 2020 by period of progression.

| | Period of progression | | | |
|---|---|---|---|---|
| | 1988-1997 n=603 | 1998-2006 n=1,541 | 2007-2015 n=2,630 | 2016+ n=1,450 |
| Years | % | % | % | % |
| 0 | 100.0 | 100.0 | 100.0 | 100.0 |
| 1 | 44.7 | 47.3 | 54.2 | 60.9 |
| 2 | 25.3 | 28.8 | 35.2 | 41.9 |
| 3 | 15.2 | 20.3 | 25.0 | 29.8 |
| 4 | 11.3 | 15.5 | 19.1 | 24.5 |
| 5 | 9.4 | 12.2 | 16.0 | |
| 6 | 7.8 | 10.1 | 13.5 | |
| 7 | 6.8 | 9.2 | 11.9 | |
| 8 | 6.1 | 8.1 | 10.8 | |
| 9 | 5.9 | 7.8 | 10.3 | |
| 10 | 5.5 | 7.0 | 9.5 | |

**Table 5f.** Observed post-progression (distant metastasis) survival of patients with fem. genitale cancer for period 1988-2020 by period of progression (N=6,224).

**Shortcuts**

| | | |
|---|---|---|
| MCR | Munich Cancer Registry, Germany | |
| | | |
| NCI | National Cancer Institute, USA | |
| SEER | Surveillance, Epidemiology, and End Results, USA | |
| UICC | Union for International Cancer Control, Geneva | |
| | | |
| DCO | Death certificate only | Death certificate provides the only notification to the registry. |
| NA | Not available | |
| NOS | Not otherwise specified | |
| | | |
| OS | Overall/Observed survival | Overall/Observed survival (Kaplan-Meier estimate)<br>Date of entry: diagnosis<br>Event: death from any cause |
| RS | Relative survival | Survival compared to "general population",<br>ratio of observed to expected survival (Ederer II method),<br>reflecting cancer specific survival |
| AS | Assembled survival | Assembled chart of<br>observed, expected, relative survival |
| CS | Conditional survival | Survival probability under the condition of surviving<br>a given period of time |
| TTP | Time to progression | Time to first progression / relapse<br>Date of entry: diagnosis<br>Event: (progression / relapse): first local-, lymph node recurrence,<br>distant metastasis or unspecified progression |
| | 1-KM | 1 minus Kaplan-Meier estimator<br>("inverse" Kaplan-Meier estimator) |
| | CI | Cumulative incidence<br>Death as competing risk (according to Kalbfleisch und Prentice) |
| PPS | Post-progression survival | Survival since first progression / relapse (Kaplan-Meier estimate)<br>Date of entry (progression / relapse): first local-, lymph node<br>recurrence, distant metastasis or unspecified progression<br>Event: death from any cause |

**Recommended Citation**

Munich Cancer Registry. Survival ICD-10 C51-C58: Fem. genitale cancer [Internet]. 2022 [updated 2022 Apr 15; cited 2022 Jun 1]. Available from: https://www.tumorregister-muenchen.de/en/facts/surv/sC5158E-ICD-10-C51-C58-Fem.-genitale-cancer-survival.pdf

**Copyright**

**Disclaimer**